BioCardia (NASDAQ:BCDA) & Black Diamond Therapeutics (NASDAQ:BDTX) Head-To-Head Review

Black Diamond Therapeutics (NASDAQ:BDTX) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Institutional and Insider Ownership

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Black Diamond Therapeutics and BioCardia”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70.00 million	1.55	$22.37 million	($0.75)	-2.52
BioCardia	$60,000.00	262.43	-$8.23 million	($0.64)	-1.62

Black Diamond Therapeutics has higher revenue and earnings than BioCardia. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Black Diamond Therapeutics has a beta of 3.32, meaning that its stock price is 232% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Profitability

This table compares Black Diamond Therapeutics and BioCardia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
BioCardia	N/A	-569.36%	-183.15%

Analyst Ratings

This is a summary of current ratings for Black Diamond Therapeutics and BioCardia, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1	2	8	0	2.64
BioCardia	1	1	1	0	2.00

Black Diamond Therapeutics presently has a consensus target price of $10.25, suggesting a potential upside of 442.33%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,303.85%. Given BioCardia’s higher possible upside, analysts plainly believe BioCardia is more favorable than Black Diamond Therapeutics.

Summary

Black Diamond Therapeutics beats BioCardia on 8 of the 13 factors compared between the two stocks.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.